Table 1

Thalidomide in relapsed-refractory patients with MM

RegimenNo. patientsCR, %Greater than PR, %PFS/EFS/TTP, %OS, %Reference
Thalidomide alone       
    T 84 2 25 50 at 3 mo 58 at 12 mo 9  
    T 169 14* 30 20 at 24 mo 48 at 24 mo 10  
    T 400 ND ND ND 69-73 at 12 mo 14  
    T 1674 ND 29 50 at 12 mo 50 at 14 mo 12  
Dexamethasone       
    TD 62 ND 56 50 at 17 mo 60 at 36 mo 17  
    TD 58 ND 46 50 at 11 mo 50 at 19 mo 17  
    TD 77 ND 41 50 at 12 mo ND 18  
    TD 44 ND 55 50 at 4 mo 50 at 13 mo 19  
    TD 58 ND 65 47 at 12 mo ND 20 † 
Melphalan       
    TM 27 ND 59 61 at 24 mo 61 at 24 mo 21  
    MivPT 24 ND 41 50 at 9 mo 50 at 14 mo 22  
    MTD 21 5 18‡ 50 at 9 mo 50 at 13 mo 23  
Doxorubicin       
    TAD 50 26 76 50 at 17 mo ND 24  
    DVd-T 49 20 75 50 at 16 mo 50 at 40 mo 25  
Cyclophosphamide       
    CDT 52 17 79 34 at 24 mo 73 at 24 mo 26  
    Pulsed CTD 53 5 60 50 at 8 mo 50 at 18 mo 27  
    ThaCyDex 71 2 55 57 at 24 mo 66 at 24 mo 28  
    HyperCTD 60 4 72 50 at 11 mo 50 at 19 mo 29  
RegimenNo. patientsCR, %Greater than PR, %PFS/EFS/TTP, %OS, %Reference
Thalidomide alone       
    T 84 2 25 50 at 3 mo 58 at 12 mo 9  
    T 169 14* 30 20 at 24 mo 48 at 24 mo 10  
    T 400 ND ND ND 69-73 at 12 mo 14  
    T 1674 ND 29 50 at 12 mo 50 at 14 mo 12  
Dexamethasone       
    TD 62 ND 56 50 at 17 mo 60 at 36 mo 17  
    TD 58 ND 46 50 at 11 mo 50 at 19 mo 17  
    TD 77 ND 41 50 at 12 mo ND 18  
    TD 44 ND 55 50 at 4 mo 50 at 13 mo 19  
    TD 58 ND 65 47 at 12 mo ND 20 † 
Melphalan       
    TM 27 ND 59 61 at 24 mo 61 at 24 mo 21  
    MivPT 24 ND 41 50 at 9 mo 50 at 14 mo 22  
    MTD 21 5 18‡ 50 at 9 mo 50 at 13 mo 23  
Doxorubicin       
    TAD 50 26 76 50 at 17 mo ND 24  
    DVd-T 49 20 75 50 at 16 mo 50 at 40 mo 25  
Cyclophosphamide       
    CDT 52 17 79 34 at 24 mo 73 at 24 mo 26  
    Pulsed CTD 53 5 60 50 at 8 mo 50 at 18 mo 27  
    ThaCyDex 71 2 55 57 at 24 mo 66 at 24 mo 28  
    HyperCTD 60 4 72 50 at 11 mo 50 at 19 mo 29  

TTP indicates time to progression; T, thalidomide; TM, thalidomide-melphalan; MivPT, intravenous melphalan-thalidomide-prednisone; MTD, melphalan-thalidomide-dexamethasone; TAD, thalidomide-pegylated lyposomal doxorubicin-dexamethasone; DVd-T, pegylated lyposomal doxorubicin-vincristine-decreased frequency dexamethasone-thalidomide; CDT, cyclophosphamide-dexamethasone-thalidomide; CTD, cyclophosphamide-thalidomide-dexamethasone; ThaCyDex, thalidomide-cyclophosphamide–dexamethasone; and ND, not determined.

*

CR plus near CR.

†

Randomized trial.

‡

Serum monoclonal protein reduction greater than 96%.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal